Patents by Inventor Meike Emma Willemijn LOGTENBERG

Meike Emma Willemijn LOGTENBERG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA-CD47 INTERACTION
    Publication number: 20220087981
    Abstract: The present invention relates to active agents or compounds as well as pharmaceutical compositions comprising said compounds, which are capable of reducing or inhibiting or blocking the enzymatic activity of the glutaminyl-peptide cyclotransferase (QPCT) protein, the glutaminyl-peptide cyclotransferase-like protein (QPCTL) protein, or combinations thereof or are capable of reducing or inhibiting the expression of QPCT gene, the QPCTL gene, or combinations thereof. Also provided are methods for screening or selecting for said compounds. The present invention further relates to a pharmaceutical composition comprising a first active agent for use in a method of treating a condition in a subject that would benefit from reducing the signaling or the binding between SIRP? and CD47 in the subject (e.g. cancer), wherein the method of treating comprises reducing expression or enzymatic activity of QPCTL, QPCT, or combinations thereof in the cell with CD47 on the surface.
    Type: Application
    Filed: April 23, 2021
    Publication date: March 24, 2022
    Applicants: Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, Academisch Ziekenhuis Leiden H.O.D. N. LUMC
    Inventors: Matthijs Raaben, Ferenc Alexander Scheeren, Meike Emma Willemijn Logtenberg, Thijn Reinout Brummelkamp, Antonius Nicolaas Maria Schumacher, Jeannette Henrica Wilhelmina Leusen
  • TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA-CD47 INTERACTION
    Publication number: 20190365717
    Abstract: The present invention relates to active agents or compounds as well as pharmaceutical compositions comprising said compounds, which are capable of reducing or inhibiting or blocking the enzymatic activity of the glutaminyl-peptide cyclotransferase (QPCT) protein, the glutaminyl-peptide cyclotransferase-like protein (QPCTL) protein, or combinations thereof or are capable of reducing or inhibiting the expression of QPCT gene, the QPCTL gene, or combinations thereof. Also provided are methods for screening or selecting for said compounds. The present invention further relates to a pharmaceutical composition comprising a first active agent for use in a method of treating a condition in a subject that would benefit from reducing the signaling or the binding between SIRP? and CD47 in the subject (e.g. cancer), wherein the method of treating comprises reducing expression or enzymatic activity of QPCTL, QPCT, or combinations thereof in the cell with CD47 on the surface.
    Type: Application
    Filed: April 26, 2019
    Publication date: December 5, 2019
    Inventors: Matthijs RAABEN, Ferenc Alexander SCHEEREN, Meike Emma Willemijn LOGTENBERG, Thijn Reinout BRUMMELKAMP, Antonius Nicolaas Maria SCHUMACHER, Jeannette Henrica Wilhelmina LEUSEN